Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 23, 2026Leukemia & lymphoma/Leukemia and lymphoma

Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJenna CiervoAPAnthony J. PerissinottiADAdam J. DiPippo

Discussion

Loading...

Member takes

Overview

Retrospective cohort study finds adding venetoclax to hypomethylating agents increases response rates without improving survival in advanced myeloproliferative neoplasms, highlighting clinical...

Key Points

  • To assess clinical outcomes and overall survival in patients with accelerated-phase and blast-phase myeloproliferative neoplasms treated with hypomethylating agents with or without venetoclax.
  • Multicenter, retrospective cohort study of 188 patients with accelerated-phase or blast-phase myeloproliferative neoplasms from the HERO consortium.
  • Evaluated outcomes between patients receiving hypomethylating agents (HMA) ± JAK inhibitors (N=94) and those receiving HMA plus venetoclax ± JAK inhibitors (N=56).
  • Analyzed primary endpoint of overall survival and secondary endpoints of response rates and allogeneic hematopoietic cell transplant rates using log-rank tests and multivariate Cox regression.
  • Overall survival was identical at a median of 9.2 months for both the HMA alone and HMA plus venetoclax cohorts (log-rank p = 0.569).
  • HMA plus venetoclax achieved significantly higher response rates for CR/CRi (36% vs. 11%, p = 0.0002) and CR/CRi/MLFS (52% vs. 16%, p < 0.0001) compared to HMA alone.
  • Rates of allogeneic hematopoietic cell transplantation did not differ significantly between groups (14% with HMA vs. 18% with HMA plus venetoclax, p = 0.51), while age and transplant receipt independently predicted survival.

Cite This Study

Ciervo et al. (2026) studied this question.

synapsesocial.com/papers/6a8aad667677a3411444580ahttps://doi.org/10.1080/10428194.2026.2711164
View Full Paper
Ask AI
Bookmark
Share